David Meeker: So, Phil, just to reinforce a couple of things that Jennifer said there. I want to remind that one of our common themes in rare disease world don’t trend it in a linear fashion. So that certainly goes for revenues and it — early on and also goes for the script. So whether it will be 80 per quarter and the like, in calls for sure or not, it will continue. That will also be lumpy, but as Jennifer said, we remain incredibly encouraged by the strength of the demand here. And the one other piece I referred you to, as Jennifer highlighted, was the 22% of physicians who were not engaged with what we’re writing. These are patients who were not on our radar. So back to the different ways patients are coming into the system. A, we may find them or B, they may find us. So again, a lot of thing.
Philip Nadeau: That’s very helpful. And then one last question on the pipeline. On the DAYBREAK data that we’re going to end the second half of the year, do you think you’ll be in a position to release results from all the gene types in the study or will it be a snapshot as to the most mature data that you have at that time?
David Meeker: Probably a blend of that answer in the sense that, as you know, remember we start off looking at 30 genes. And then during the course of the trial, we amended that based on some early results of genes not being so interesting and also some of the genes were just so rare that we really couldn’t enroll them. So we stopped looking for them, which doesn’t mean they’re not out there. It’s just that they’ll not be part of DAYBREAK. So we’ll try to give you a sense of — we will give you a sense of sort of the larger landscape and how we narrowed it down, but the areas of interest will be those genes for which we focus down on, we’re able to enroll enough patients to draw some conclusions, which will be a number much smaller than the 30 and we set the expectation that will be probably on the order of five plus or minus, maybe as much as 10, but it’s — that’s going to be the kind of data and the focus is still here.
Philip Nadeau : That’s very helpful. Thanks again for taking our questions.
David Meeker: Thank you.
Operator: Please standby for our next question. Our next question comes from Derek Archila with Wells Fargo. Your line is now open.
Derek Archila: Hey, good morning everyone and thanks for taking the questions. Congrats on all the progress here. Just a couple of questions from us. I guess maybe first, as we are now in 2023, maybe just any commentary on more recent trends for scripts and particularly around BBS patients? And is there any seasonality as you should think about kind of this first quarter relative to the rest of the year? And then second question, given that you have 100 reimbursed scripts, I guess, simple math, does that kind of imply like a $30 million kind of annual rate here in terms of, if all those patients stay on therapy. And I guess if that’s true, I guess, how does that impact your thinking on where current consensus is, which is like $35 million to $66 million for 2023? Thanks.
David Meeker: Thanks, Derek. Thanks a lot. So what we’ll do is, I’ll let Hunter the consensus question just to
Hunter Smith: Yes, I don’t think we want to get into the commenting on consensus. It’s inconsistent with our not giving guidance. Having said that, the spread is quite wide and we expect as we continue to — as we continue to execute, I do expect the range of estimates to narrow.
David Meeker: Jennifer, several questions there. One on just the overall trend again and seasonality quarter on quarter in rare disease world, this one specifically.
